Get the Stockscreener App
23.39
2.14%
0.49
After Hours:
23.46
0.07
+0.30%
Immunome Inc stock is traded at $23.39, with a volume of 648.62K.
It is up +2.14% in the last 24 hours and up +14.88% over the past month.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
See More
Previous Close:
$22.90
Open:
$23.08
24h Volume:
648.62K
Relative Volume:
0.44
Market Cap:
$2.65B
Revenue:
$6.94M
Net Income/Loss:
$-212.39M
P/E Ratio:
-9.6334
EPS:
-2.428
Net Cash Flow:
$-200.60M
1W Performance:
+7.79%
1M Performance:
+14.88%
6M Performance:
+43.06%
1Y Performance:
+216.08%
1-Day Range:
$22.50
$23.45
1-Week Range:
$21.42
$23.68
52-Week Range:
$6.96
$27.65
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
23.39 | 2.59B | 6.94M | -212.39M | -200.60M | -2.428 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Truist | Buy |
| Sep-22-25 | Initiated | Goldman | Buy |
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead - FXEmpire
Death Cross: Can Immunome Inc be the next market leader2026 Technicals & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Stock Analysis: Is Immunome Inc part of any ETF2026 Retail Activity & Daily Volume Surge Signals - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (IMNM) Movement - Stock Traders Daily
IMNM News | IMMUNOME INC (NASDAQ:IMNM) - ChartMill
Death Cross: Is Immunome Inc gaining market share2026 Key Lessons & Technical Pattern Based Buy Signals - baoquankhu1.vn
LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Immunome CSO Sells Shares: Transaction Details & Company SnapshotNews and Statistics - IndexBox
Immunome (IMNM) Is Up 11.4% After CEO Share Buy And Positive Phase III DataWhat's Changed - Sahm
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More - AOL.com
Insider Sell: What is the long term forecast for Immunome Inc stockDividend Hike & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More - The Motley Fool
A Look At Immunome (IMNM) Valuation After Oncology Progress EPS Upgrades And CEO Insider Buying - Sahm
Immunome, Inc. (IMNM) stock price, news, quote and history - Yahoo Finance Singapore
Immunome Inc (IMNM) CSO Higgins sells $204,238 in stock By Investing.com - Investing.com UK
Immunome CFO Rosett sells $1.4m in shares By Investing.com - Investing.com Canada
Immunome Inc (IMNM) CSO Higgins sells $204,238 in stock - Investing.com
Immunome CFO Rosett sells $1.4m in shares - Investing.com
Insider Selling: Immunome (NASDAQ:IMNM) Insider Sells 9,438 Shares of Stock - MarketBeat
Insider Selling: Immunome (NASDAQ:IMNM) CFO Sells $1,424,800.00 in Stock - MarketBeat
Immunome (IMNM) CSO pre-planned 9,438-share sale under Rule 10b5-1 - Stock Titan
Immunome (IMNM) CFO exercises 71,561 options and sells 65,000 shares - Stock Titan
IMNM (NASDAQ: IMNM) Form 144/A: 65,000 shares proposed sale via Fidelity - Stock Titan
Tema Etfs LLC Has $2.19 Million Position in Immunome, Inc. $IMNM - MarketBeat
SG Americas Securities LLC Raises Stock Position in Immunome, Inc. $IMNM - MarketBeat
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
Immunome reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Proposed common-share sale reported by IMNM (NASDAQ: IMNM) - Stock Titan
IMNM (NASDAQ: IMNM) files Form 144 for proposed stock sales - Stock Titan
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last? - qz.com
Immunome (NASDAQ: IMNM) CSO gifts 6,291 shares, retains 31,438 - Stock Titan
Immunome (IMNM) Surges by 13.3%: Can This Momentum Continue? - Bitget
Tuesday’s insider activity: CEO doubles down on biotech stock By Investing.com - Investing.com South Africa
Volume Summary: Can Immunome Inc be the next market leader2026 Trade Ideas & Growth Focused Stock Pick Reports - baoquankhu1.vn
Goldman Sachs Initiates Coverage of Immunome (IMNM) with Buy Recommendation - MSN
Immunome (NASDAQ:IMNM) Stock Price Up 9.4%What's Next? - MarketBeat
Insider Buying: Clay Siegall Acquires Shares of Immunome Inc (IM - GuruFocus
Immunome Insider Bought Shares Worth $500,602, According to a Recent SEC Filing - marketscreener.com
Immunome CEO Clay Siegall buys $500k in shares By Investing.com - Investing.com South Africa
Immunome CEO Clay Siegall buys $500k in shares - Investing.com
Immunome (IMNM) CEO adds 25,450 shares in $19.67 stock purchase - Stock Titan
Immunome Inc Stock: Clinical-Stage Biotech Targeting Cancer and Infectious Diseases with Innovative - AD HOC NEWS
Recap Report: What is the long term forecast for Immunome Inc stockWeekly Investment Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn
Vanguard disaggregates holdings; IMNM shows 0 shares after realignment (IMNM) - Stock Titan
Don't Ignore The Insider Selling In Immunome - simplywall.st
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):